178 related articles for article (PubMed ID: 21084039)
41. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
42. The safety of ustekinumab for the treatment of psoriatic arthritis.
López-Ferrer A; Laiz A; Puig L
Expert Opin Drug Saf; 2017 Jun; 16(6):733-742. PubMed ID: 28441904
[TBL] [Abstract][Full Text] [Related]
43. How effective is ustekinumab in controlling psoriatic arthritis?
Bonifati C; Graceffa D
Dermatol Ther; 2016 May; 29(3):155-9. PubMed ID: 26626908
[TBL] [Abstract][Full Text] [Related]
44. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.
Zhou H; Hu C; Zhu Y; Lu M; Liao S; Yeilding N; Davis HM
J Clin Pharmacol; 2010 Mar; 50(3):257-67. PubMed ID: 19934030
[TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
[TBL] [Abstract][Full Text] [Related]
46. Ustekinumab for psoriatic arthritis.
Cuchacovich RS; Espinoza LR
Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
[No Abstract] [Full Text] [Related]
47. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
48. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
Smolen JS; Agarwal SK; Ilivanova E; Xu XL; Miao Y; Zhuang Y; Nnane I; Radziszewski W; Greenspan A; Beutler A; Baker D
Ann Rheum Dis; 2017 May; 76(5):831-839. PubMed ID: 28087506
[TBL] [Abstract][Full Text] [Related]
49. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
50. Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.
Almirall M; Rodriguez J; Mateo L; Carrascosa JM; Notario J; Gallardo F
Clin Rheumatol; 2017 Feb; 36(2):439-443. PubMed ID: 27817126
[TBL] [Abstract][Full Text] [Related]
51. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
52. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
[TBL] [Abstract][Full Text] [Related]
53. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Khanna R; Preiss JC; MacDonald JK; Timmer A
Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
[TBL] [Abstract][Full Text] [Related]
54. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
55. Population pharmacokinetics of erythropoietin in critically ill subjects.
Chakraborty A; Natarajan J; Guilfoyle M; Morgan N; Vercammen E; Cheung W
J Clin Pharmacol; 2005 Feb; 45(2):193-202. PubMed ID: 15647412
[TBL] [Abstract][Full Text] [Related]
56. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
57. Ustekinumab.
Cingoz O
MAbs; 2009; 1(3):216-21. PubMed ID: 20069753
[TBL] [Abstract][Full Text] [Related]
58. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
[TBL] [Abstract][Full Text] [Related]
59. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
Fasanmade AA; Adedokun OJ; Ford J; Hernandez D; Johanns J; Hu C; Davis HM; Zhou H
Eur J Clin Pharmacol; 2009 Dec; 65(12):1211-28. PubMed ID: 19756557
[TBL] [Abstract][Full Text] [Related]
60. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
